237 related articles for article (PubMed ID: 7824731)
21. Malignant melanoma: staging with whole-body positron emission tomography and 2-[F-18]-fluoro-2-deoxy-D-glucose.
Steinert HC; Huch Böni RA; Buck A; Böni R; Berthold T; Marincek B; Burg G; von Schulthess GK
Radiology; 1995 Jun; 195(3):705-9. PubMed ID: 7753998
[TBL] [Abstract][Full Text] [Related]
22. PET FDG studies in oncology.
Hawkins RA; Hoh CK
Nucl Med Biol; 1994 Jul; 21(5):739-47. PubMed ID: 9241650
[TBL] [Abstract][Full Text] [Related]
23. Detection of malignant tumors: whole-body PET with fluorine 18 alpha-methyl tyrosine versus FDG--preliminary study.
Inoue T; Koyama K; Oriuchi N; Alyafei S; Yuan Z; Suzuki H; Takeuchi K; Tomaru Y; Tomiyoshi K; Aoki J; Endo K
Radiology; 2001 Jul; 220(1):54-62. PubMed ID: 11425972
[TBL] [Abstract][Full Text] [Related]
24. Assessment of response to cancer therapy using fluorine-18-fluorodeoxyglucose and positron emission tomography.
Ichiya Y; Kuwabara Y; Otsuka M; Tahara T; Yoshikai T; Fukumura T; Jingu K; Masuda K
J Nucl Med; 1991 Sep; 32(9):1655-60. PubMed ID: 1880564
[TBL] [Abstract][Full Text] [Related]
25. High [18F]FDG uptake in primary cerebral lymphoma: a PET study.
Kuwabara Y; Ichiya Y; Otsuka M; Miyake Y; Gunasekera R; Hasuo K; Masuda K; Takeshita I; Fukui H
J Comput Assist Tomogr; 1988; 12(1):47-8. PubMed ID: 3257221
[TBL] [Abstract][Full Text] [Related]
26. FDG-PET screening for cerebral metastases in patients with suspected malignancy.
Larcos G; Maisey MN
Nucl Med Commun; 1996 Mar; 17(3):197-8. PubMed ID: 8692485
[TBL] [Abstract][Full Text] [Related]
27. Uptake of 2-deoxy, 2-(18F) fluoro-D-glucose in bladder cancer: animal localization and initial patient positron emission tomography.
Harney JV; Wahl RL; Liebert M; Kuhl DE; Hutchins GD; Wedemeyer G; Grossman HB
J Urol; 1991 Feb; 145(2):279-83. PubMed ID: 1988718
[TBL] [Abstract][Full Text] [Related]
28. FDG-PET in pediatric posterior fossa brain tumors.
Hoffman JM; Hanson MW; Friedman HS; Hockenberger BM; Oakes WJ; Halperin EC; Coleman RE
J Comput Assist Tomogr; 1992; 16(1):62-8. PubMed ID: 1729308
[TBL] [Abstract][Full Text] [Related]
29. Can 3'-Deoxy-3'-((18)F) Fluorothymidine Out Perform 2-Deoxy-2-((18)F) Fluoro-D-Glucose Positron Emission Tomography/Computed Tomography in the Diagnosis of Cervical Lymphadenopathy in Patients With Oral/Head and Neck Cancer?
Schaefferkoetter JD; Carlson ER; Heidel RE
J Oral Maxillofac Surg; 2015 Jul; 73(7):1420-8. PubMed ID: 25869746
[TBL] [Abstract][Full Text] [Related]
30. The utility of 2-deoxy-2-[18F]fluoro-D-glucose-positron emission tomography and combined positron emission tomography and computed tomography in lymphoma and melanoma.
Macapinlac HA
Mol Imaging Biol; 2004; 6(4):200-7. PubMed ID: 15262235
[TBL] [Abstract][Full Text] [Related]
31. Fluorine-18-fluorodeoxyglucose PET imaging of soft-tissue sarcoma.
Nieweg OE; Pruim J; van Ginkel RJ; Hoekstra HJ; Paans AM; Molenaar WM; Koops HS; Vaalburg W
J Nucl Med; 1996 Feb; 37(2):257-61. PubMed ID: 8667056
[TBL] [Abstract][Full Text] [Related]
32. Characterization of chest masses by FDG positron emission tomography.
Hübner KF; Buonocore E; Singh SK; Gould HR; Cotten DW
Clin Nucl Med; 1995 Apr; 20(4):293-8. PubMed ID: 7788982
[TBL] [Abstract][Full Text] [Related]
33. Identification of early recurrence of primary central nervous system tumors by [18F]fluorodeoxyglucose positron emission tomography.
Glantz MJ; Hoffman JM; Coleman RE; Friedman AH; Hanson MW; Burger PC; Herndon JE; Meisler WJ; Schold SC
Ann Neurol; 1991 Apr; 29(4):347-55. PubMed ID: 1929205
[TBL] [Abstract][Full Text] [Related]
34. Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET).
Duhaylongsod FG; Lowe VJ; Patz EF; Vaughn AL; Coleman RE; Wolfe WG
J Thorac Cardiovasc Surg; 1995 Jul; 110(1):130-9; discussion 139-40. PubMed ID: 7609536
[TBL] [Abstract][Full Text] [Related]
35. 2-(fluorine-18)-fluoro-2-deoxy-D-glucose PET in detection of pancreatic cancer: value of quantitative image interpretation.
Stollfuss JC; Glatting G; Friess H; Kocher F; Berger HG; Reske SN
Radiology; 1995 May; 195(2):339-44. PubMed ID: 7724750
[TBL] [Abstract][Full Text] [Related]
36. Normal thymic uptake of FDG on PET imaging.
Patel PM; Alibazoglu H; Ali A; Fordham E; LaMonica G
Clin Nucl Med; 1996 Oct; 21(10):772-5. PubMed ID: 8896924
[TBL] [Abstract][Full Text] [Related]
37. Noninvasive grading of musculoskeletal tumors using PET.
Adler LP; Blair HF; Makley JT; Williams RP; Joyce MJ; Leisure G; al-Kaisi N; Miraldi F
J Nucl Med; 1991 Aug; 32(8):1508-12. PubMed ID: 1869970
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET.
Adler LP; Crowe JP; al-Kaisi NK; Sunshine JL
Radiology; 1993 Jun; 187(3):743-50. PubMed ID: 8497624
[TBL] [Abstract][Full Text] [Related]
39. Pheochromocytomas that do not accumulate metaiodobenzylguanidine: localization with PET and administration of FDG.
Shulkin BL; Koeppe RA; Francis IR; Deeb GM; Lloyd RV; Thompson NW
Radiology; 1993 Mar; 186(3):711-5. PubMed ID: 8430179
[TBL] [Abstract][Full Text] [Related]
40. FDG-PET for predicting the prognosis of malignant lymphoma.
Okada J; Oonishi H; Yoshikawa K; Itami J; Uno K; Imaseki K; Arimizu N
Ann Nucl Med; 1994 Aug; 8(3):187-91. PubMed ID: 7811561
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]